GCNT2

GCNT2 encodes a β1,6-N-acetylglucosaminyltransferase that constructs I-branched poly-N-acetyllactosamine glycans, acting through tissue-specific isoforms to govern lens transparency, erythrocyte I/i blood group identity, and the glycosylation state of cell-surface receptors (PMID:15161861, PMID:30135430). In glycan synthesis, GCNT2 cooperates with β3GnT2: the two enzymes together generate N-linked poly-N-acetyllactosamine on cell-surface glycoproteins, with GCNT2 supplying the β1,6-branch that licenses chain extension, an activity neither enzyme produces alone (PMID:24105809). The locus is organized into alternative first exons that generate functionally segregated isoforms—the exon-1B-driven GCNT2B isoform is specifically required for lens function, while the GCNT2C isoform is the sole transcript expressed in red blood cells and dictates I-antigen display (PMID:27609212). Loss-of-function lesions—nonsense mutation, large Alu-mediated genomic deletions, or isoform-restricted truncating variants—abolish I-branching activity and cause autosomal recessive congenital cataracts and the adult i blood group phenotype, with deletions sparing exon 1C producing cataracts without the blood group change (PMID:15161861, PMID:21761136, PMID:27609212). In cancer, I-branched glycans installed by GCNT2 decorate IGF receptors and integrins to dampen their signaling and restrain melanoma growth, and GCNT2-dependent I-antigens are required for NK-cell recognition of tumor cells (PMID:30135430, PMID:40149658); expression is restrained by miR-199a/b-5p, whose loss during EMT permits GCNT2 upregulation (PMID:28542779).

1. 2004 Medium

   Established that GCNT2 enzymatic activity is jointly required in lens and erythroid lineages, linking a single glycosyltransferase to two distinct phenotypes.

   Evidence Linkage mapping and direct sequencing identifying a homozygous W328X nonsense mutation with blood group typing in cataract patients

   PMID:15161861

   Open questions at the time

   • Did not resolve which transcript/isoform mediates each phenotype
   • No biochemical reconstitution of lost enzymatic activity
2. 2011 Medium

   Showed that structural genomic loss at the locus, not only point mutation, abolishes GCNT2 function, defining a recombination-driven mutational mechanism.

   Evidence Homozygosity mapping and breakpoint sequencing of a ~93 kb Alu-Alu-mediated deletion with phenotypic confirmation

   PMID:21761136

   Open questions at the time

   • Did not dissect isoform-specific contributions since deletion removed multiple exons
3. 2014 Medium

   Defined the biochemical logic of I-branch synthesis, showing GCNT2 must act in concert with β3GnT2 to extend poly-N-acetyllactosamine chains.

   Evidence Co-transfection of GCNT2 and β3GnT2 in HEK293T cells with cell-surface glycan readout on adenylyl cyclase 3

   PMID:24105809

   Open questions at the time

   • Enzymatic kinetics and stoichiometry of cooperation not determined
   • Endogenous substrate range not mapped
4. 2016 Medium

   Resolved the genotype-phenotype puzzle by assigning lens function to the exon-1B GCNT2B isoform and erythroid I-antigen to GCNT2C.

   Evidence Whole-exome sequencing and deletion mapping with isoform-specific genotype-phenotype correlation

   PMID:27609212

   Open questions at the time

   • No direct demonstration of isoform expression in human lens tissue
   • Regulatory basis of tissue-specific exon usage unknown
5. 2017 Medium

   Identified a post-transcriptional control circuit, showing miR-199a/b-5p directly represses GCNT2 and links its expression to EMT state.

   Evidence Luciferase reporter and RISC-trap assays plus EMT induction in colon cancer cells

   PMID:28542779

   Open questions at the time

   • Functional consequence of GCNT2 derepression on tumor behavior not tested here
   • Other regulators of GCNT2 not addressed
6. 2018 High

   Established GCNT2 as a tumor-suppressive glycosylation switch in melanoma, with I-branched glycans dampening IGF receptor and integrin signaling.

   Evidence Xenograft, colony formation, overexpression/knockdown, glycan profiling and receptor signaling assays

   PMID:30135430

   Open questions at the time

   • Direct glycan site mapping on individual receptors not resolved
   • Mechanism of signaling attenuation by branching not fully defined
7. 2018 Medium

   Revealed context-dependent, opposite tumor behavior, with GCNT2 promoting EMT, migration and invasion in esophageal carcinoma cells.

   Evidence Overexpression and knockdown in ESCC cell lines with EMT marker Western blots and migration/invasion assays

   PMID:30575058

   Open questions at the time

   • No in vivo validation
   • Molecular basis of pro-EMT effect unidentified
   • Reconciliation with tumor-suppressive role in melanoma unresolved
8. 2025 Medium

   Connected GCNT2 glycans to anti-tumor immunity, showing I-antigens are required for NK-cell recognition of bladder cancer cells.

   Evidence Overexpression/knockdown in bladder cancer lines with in vitro NK cytotoxicity assays and granule-release ELISA

   PMID:40149658

   Open questions at the time

   • NK receptor that reads I-antigen not identified
   • No in vivo immune validation
9. 2025 Low

   Implicated GCNT2 in osteoblast differentiation upstream of PI3K/AKT/mTOR signaling.

   Evidence Knockdown in MC3T3-E1 osteoblasts with differentiation markers and LY294002 inhibitor rescue

   PMID:41298859

   Open questions at the time

   • Pharmacological inhibitor only, no direct pathway confirmation
   • Single cell-line model, no in vivo data
   • Glycan substrate linking GCNT2 to PI3K signaling not identified
10. 2026 Low

    Reinforced that the exon-1B GCNT2B transcript is clinically required for lens function via an isoform-restricted truncating variant.

    Evidence Next-generation sequencing and copy-number mapping with genotype-phenotype correlation in a cataract case

    PMID:41813616

    Open questions at the time

    • Single case report, no biochemical validation
    • Variant effect on enzyme activity not measured

• How GCNT2's I-branching produces opposite tumor outcomes across tissues, and which receptors and glycan sites mediate immune and signaling effects, remains unresolved.
• No structural model of isoform-specific substrate selection
• Direct glycan acceptor sites on IGF receptors/integrins unmapped
• NK receptor recognizing I-antigen unidentified